We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

14 hedge funds and large institutions have $4.76M invested in Summit Therapeutics in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more funds holding

Funds holding: 11 → 14 (+3)

0.01% less ownership

Funds ownership: 2.73% → 2.72% (-0.01%)

9% less capital inflows, than outflows

Capital inflows: $77.2K | Capital outflows: $84.7K

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$37.3K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$35.8K
3
Wells Fargo
Wells Fargo
California
+$2.7K
4
UBS Group
UBS Group
Switzerland
+$1.37K

Top Sellers

Rank Fund Capital Flow
1
Polar Capital
Polar Capital
United Kingdom
-$60.4K
2
Morgan Stanley
Morgan Stanley
New York
-$22K
3
Deutsche Bank
Deutsche Bank
Germany
-$2.3K

SMMT Hedge Fund Activity: Q3 2019 in Review

14 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2019, worth a combined $4.76M — up 41% from $3.37M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new SMMT positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $37.3K. The largest seller was Polar Capital, cutting an estimated $60.4K.

  • 14 institutional investors held Summit Therapeutics (SMMT) as of Q3 2019, up from 11 in Q2 2019.
  • Funds reported $4.76M of Summit Therapeutics stock for Q3 2019, up 41% quarter-over-quarter.
  • 3 funds opened new Summit Therapeutics positions in Q3 2019 and 0 closed out, a net change of +3 holders.
  • The largest Summit Therapeutics buyer in Q3 2019 was Renaissance Technologies, an estimated $37.3K added.
  • The largest Summit Therapeutics seller in Q3 2019 was Polar Capital, an estimated $60.4K sold.

Based on aggregated 13F filings for Q3 2019.